Furthermore, zoledronic acid suppresses breast cancer growth through inhibition of the AKT/forkhead box protein O3a (FOXO3a)-mediated expression of the extracellular matrix-associated protein CCN family member 1 (CCN1). The gene discussed is CCN1; the disease is breast carcinoma.